<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04086173</url>
  </required_header>
  <id_info>
    <org_study_id>00000</org_study_id>
    <nct_id>NCT04086173</nct_id>
  </id_info>
  <brief_title>Probiotics on Body Composition and Insulin Resistance in Patients With Obesity and Its Association With Gut Microbiota</brief_title>
  <official_title>Effects of Probiotic Treatment on Body Composition and Insulin Resistance in Patients With Obesity Grade II and III and Its Association With Changes in Intestinal Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de México Dr. Eduardo Liceaga</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Italmex Pharma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medix Farma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Polytechnic Institute, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General de México Dr. Eduardo Liceaga</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the modifications in body composition and insulin resistance
      state in patients with grade II and III obesity included in an interventional lifestyle
      changes program and treated with probiotics (1 x 1011 CFU) or placebo for 16 weeks and its
      associations with intestinal microbiota behaviour
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized placebo-controlled clinical trial will take place in which both arms will be
      included in an interventional lifestyle changes program at the Clinic for Integral Treatment
      of patients with Diabetes and Obesity. The study group will be treated with probiotics (1 x
      1011 CFU) for 16 weeks and will be compared to a control group who will receive placebo.

      Changes in body composition (weight, BMI, fat percentage, fat mass, lean body mass) and
      insulin resistance indexes (HOMA, insulin sensitivity index and Quicki) will be evaluated in
      patients with obesity receiving probiotics (1 x 1011 CFU) for 16 weeks, and compared to a
      placebo group.

      Changes in metabolic profile (glucose tolerance test, glycosylated haemoglobin, lipid
      profile, leptin and transaminases) in patients with obesity receiving probiotics (1 x 1011
      CFU) for 16 weeks, and compared to a placebo group.

      Changes in microRNAs profile (miR-133 and miR-27 in patients with obesity receiving
      probiotics (1 x 1011 CFU) for 16 weeks, and compared to a placebo group.

      The threshold for basic tastes will be evaluated (salted, bitter, acid, sweet) and will be
      evaluated in those patients receiving probiotics (1 x 1011 CFU) for 16 weeks, and compared to
      the group receiving only placebo.

      Changes in intestinal microbiota behaviour will be evaluated in participants with obesity
      receiving probiotics (1 x 1011 CFU) for 16 weeks, and compared to the group receiving
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blinded randomized placebo-controlled clinical assay</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Neither the participant nor the Care provider administrating treatment will know the type of treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in fat mass in patients with obesity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in fat mass kilograms after probiotics treatment in patients with obesity, by bioelectrical impedance analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in fat percentage in patients with obesity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in fat percentage after probiotics treatment in patients with obesity, by bioelectrical impedance analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in body mass index in patients with obesity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in body mass index after probiotics treatment in patients with obesity. Calculated with the weight in kilograms divided by the square of the height in meters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in weight in patients with obesity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in weight kilograms after probiotics treatment in patients with obesity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in lean body mass in patients with obesity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in lean body mass kilograms after probiotics treatment in patients with obesity, by bioelectrical impedance analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Insulin resistance indexes</measure>
    <time_frame>16 weeks</time_frame>
    <description>Modification in HOMA index after probiotics treatment in patients with obesity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Insulin sensitivity indexes</measure>
    <time_frame>16 weeks</time_frame>
    <description>Modification in insulin sensitivity index after probiotics treatment in patients with obesity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Quicki insulin sensitivity index</measure>
    <time_frame>16 weeks</time_frame>
    <description>Modification in Quicki index after probiotics treatment in patients with obesity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose tolerance test</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in glucose tolerance test after treatment with probiotics in patients with obesity. By using plasma concentrations of insulin and glucose obtained during 120 min of a standard (75 g glucose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycated haemoglobin</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in percentage glycated haemoglobin after treatment with probiotics in patients with obesity. Obtain by capillary electrophoresis system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in triglycerides</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in triglycerides (mg/dL) after treatment with probiotics in patients with obesity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total cholesterol</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in total cholesterol (mg/dL) after treatment with probiotics in patients with obesity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HDL cholesterol</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in HDL cholesterol (mg/dL) after treatment with probiotics in patients with obesity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LDL cholesterol</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in LDL cholesterol (mg/dL) after treatment with probiotics in patients with obesity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in uric acid</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in uric acid (mg/dL) after treatment with probiotics in patients with obesity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in aspartate aminotransferase</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in aspartate aminotransferase (U/L) after treatment with probiotics in patients with obesity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in alanine aminotransferase</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in alanine aminotransferase (U/L) after treatment with probiotics in patients with obesity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in leptin</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in leptin (ng/mL) after treatment with probiotics in patients with obesity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in microRNAs</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate changes in miR-133 and miR-27 after treatment with probiotics in patients with obesity</description>
  </other_outcome>
  <other_outcome>
    <measure>Compare threshold for basic tastes</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate differences in basic taste thresholds (sour, salty, sweet and bitter) after treatment with probiotics in patients with obesity</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in intestinal microbiota</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluate differences in intestinal microbiota behaviour after treatment with probiotics in patients with obesity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <condition>Microbial Colonization</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of probiotics for 16 weeks. Probiotics (LACTIPAN®) include 2.5 billion CFU of 6 different strains of live microorganisms, such as Lactobacillus acidophilus (1.0 x 109 CFU), Lactobacillus casei (1.0 x 109 CFU), Lactobacillus rhamnosus (4.4 x 108 CFU), Lactobacillus plantarum (1.76 x 108 CFU), Bifidobacterium infantis (2.76 x 107 CFU), Streptococcus thermophilus (6.66 x 105 CFU) and 50 mg of oligofructose enriched inulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomly assigned to receive a daily nightly dose (4 capsules) of placebo for 16 weeks. Placebo presentation will have the same aspect as those of the probiotic treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Probiotics will be administered at night and will consist of 4 capsules</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with grade II y III obesity (IMC &gt; or = 35 Kg/m2), who receive the initial
             evaluation at the Integral Attention Clinic for Diabetes and Obesity at Hospital
             General de México

          -  Patients who signed informed consent.

        Exclusion Criteria:

          -  Diabetes mellitus 2

          -  Secondary causes of obesity (hypothyroidism, Cushing syndrome).

          -  Patients receiving pharmacological treatment that may affect lipid or glucose
             metabolism.

          -  Patients who received broad-spectrum antibiotics during the 4 previous weeks.

          -  Ingestion of products that contain probiotics.

          -  Relevant changes in diet habits during the 4 previous weeks

          -  Intestinal Malabsorption disorders ( inflammatory bowel disease, chronic diarrhea, C.
             difficile infection).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nayely Garibay-Nieto, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de Mexico Eduardo Liceaga</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nayely Garibay, MSc</last_name>
    <phone>+525546037000</phone>
    <email>gngaribay@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alejandro Velasco, MSc</last_name>
    <phone>+525541449172</phone>
    <email>jano_vm@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de México &quot;Dr. Eduardo Liceaga&quot;</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Velasco Medina, MSc</last_name>
      <phone>5541449172</phone>
      <email>jano_vam@yahoo.com.mx</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Banegas JR, López-García E, Gutiérrez-Fisac JL, Guallar-Castillón P, Rodríguez-Artalejo F. A simple estimate of mortality attributable to excess weight in the European Union. Eur J Clin Nutr. 2003 Feb;57(2):201-8.</citation>
    <PMID>12571650</PMID>
  </reference>
  <reference>
    <citation>Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology. 2009 Jan;136(1):65-80. doi: 10.1053/j.gastro.2008.10.080. Epub 2008 Nov 19. Review.</citation>
    <PMID>19026645</PMID>
  </reference>
  <reference>
    <citation>Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 2001 Feb 2;291(5505):881-4.</citation>
    <PMID>11157169</PMID>
  </reference>
  <reference>
    <citation>Jalanka J, Mattila E, Jouhten H, Hartman J, de Vos WM, Arkkila P, Satokari R. Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Med. 2016 Oct 11;14(1):155.</citation>
    <PMID>27724956</PMID>
  </reference>
  <reference>
    <citation>Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006 Dec 21;444(7122):1022-3.</citation>
    <PMID>17183309</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de México Dr. Eduardo Liceaga</investigator_affiliation>
    <investigator_full_name>Nayely Garibay Nieto</investigator_full_name>
    <investigator_title>Head Child and Adolescent Obesity Clinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

